These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21272100)

  • 1. Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.
    Prasad K; Tarasewicz E; Strickland PA; O'Neill M; Mitchell SN; Merchant K; Tep S; Hilton K; Datwani A; Buttini M; Mueller-Steiner S; Richfield EK
    Eur J Neurosci; 2011 Feb; 33(4):642-56. PubMed ID: 21272100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
    Rathke-Hartlieb S; Kahle PJ; Neumann M; Ozmen L; Haid S; Okochi M; Haass C; Schulz JB
    J Neurochem; 2001 May; 77(4):1181-4. PubMed ID: 11359883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
    Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
    Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
    Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M
    Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss.
    Trudler D; Sanz-Blasco S; Eisele YS; Ghatak S; Bodhinathan K; Akhtar MW; Lynch WP; Piña-Crespo JC; Talantova M; Kelly JW; Lipton SA
    J Neurosci; 2021 Mar; 41(10):2264-2273. PubMed ID: 33483428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
    Kahle PJ; Neumann M; Ozmen L; Muller V; Jacobsen H; Schindzielorz A; Okochi M; Leimer U; van Der Putten H; Probst A; Kremmer E; Kretzschmar HA; Haass C
    J Neurosci; 2000 Sep; 20(17):6365-73. PubMed ID: 10964942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
    Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
    Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
    Schell H; Hasegawa T; Neumann M; Kahle PJ
    Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.
    Rockenstein E; Nuber S; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Trejo-Morales M; Gerez J; Picotti P; Jensen PH; Campioni S; Riek R; Winkler J; Gage FH; Winner B; Masliah E
    Brain; 2014 May; 137(Pt 5):1496-513. PubMed ID: 24662516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
    Kahle PJ
    Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain.
    Delenclos M; Faroqi AH; Yue M; Kurti A; Castanedes-Casey M; Rousseau L; Phillips V; Dickson DW; Fryer JD; McLean PJ
    Acta Neuropathol Commun; 2017 Jun; 5(1):51. PubMed ID: 28645308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.
    Diepenbroek M; Casadei N; Esmer H; Saido TC; Takano J; Kahle PJ; Nixon RA; Rao MV; Melki R; Pieri L; Helling S; Marcus K; Krueger R; Masliah E; Riess O; Nuber S
    Hum Mol Genet; 2014 Aug; 23(15):3975-89. PubMed ID: 24619358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice.
    Schell H; Boden C; Chagas AM; Kahle PJ
    PLoS One; 2012; 7(11):e50245. PubMed ID: 23209687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
    Stefanova N; Kaufmann WA; Humpel C; Poewe W; Wenning GK
    Acta Neuropathol; 2012 Jul; 124(1):51-65. PubMed ID: 22491959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.
    Al-Wandi A; Ninkina N; Millership S; Williamson SJ; Jones PA; Buchman VL
    Neurobiol Aging; 2010 May; 31(5):796-804. PubMed ID: 19097673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
    Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
    Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.